Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
about
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?Protein biomarkers for subtyping breast cancer and implications for future research.Impact of 2013 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2 Fluorescent In Situ Hybridization Testing in Breast Cancers : Experience From a National Reference Laboratory.Impact of 2013 ASCO/CAP HER2 reporting guidelines in breast cancer: An assessment study from Indian oncology centre that primarily performs HER2 IHC testing with special emphasis on IHC equivocal category.Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough?HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer.Inconsistent Results With Different Secondary Reflex Assays for Resolving HER2 Status.Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study.Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2
P2860
Q33664216-463EB219-1AC5-4DD5-92C2-DF1A607DF225Q36087126-5B2661C9-86FF-49E7-83FE-10C6E5D1679AQ38729111-8CC8BB0C-E9DE-48DE-9C60-99A6CFF39287Q40338226-D793C69B-1687-4436-AF27-CB53AE881F4FQ42316809-9BA5D826-AC5E-4DD2-AFD5-C049AF8B58B3Q46387180-041CBC7A-166F-4A22-B062-66C324C57B9AQ47164059-EE6036A6-177C-4279-B81E-BDC961F4F2F9Q47261659-AB6C361D-87D6-44AC-84F2-E16D8038E1C7Q47716532-0C1646A1-7DD0-4C3F-8C34-C55DF6611635Q48101471-55A6CC0F-D4FE-43D4-B809-2CE7653B2332Q48155048-17E5A4ED-3400-4A82-A87B-7ADB8D6F7D95Q51175484-5C4C4FAF-1C8D-4B6D-94E3-5A1C7CF4A466Q51367692-9D6904AD-133B-44F9-A43E-E7C1BEFE3B76Q53095268-96418538-CCF4-444D-9A6D-C295D232D1A2Q55032245-2A9DCD8B-8EB3-4A60-A74B-DBB24528DB42Q57477210-3965211A-F9B0-462D-8DB2-F014E71FCE39
P2860
Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Impact of Modified 2013 ASCO/C ...... t Cancer. One Year Experience.
@ast
Impact of Modified 2013 ASCO/C ...... t Cancer. One Year Experience.
@en
type
label
Impact of Modified 2013 ASCO/C ...... t Cancer. One Year Experience.
@ast
Impact of Modified 2013 ASCO/C ...... t Cancer. One Year Experience.
@en
prefLabel
Impact of Modified 2013 ASCO/C ...... t Cancer. One Year Experience.
@ast
Impact of Modified 2013 ASCO/C ...... t Cancer. One Year Experience.
@en
P2860
P1433
P1476
Impact of Modified 2013 ASCO/C ...... t Cancer. One Year Experience.
@en
P2860
P304
P356
10.1371/JOURNAL.PONE.0140652
P407
P577
2015-10-16T00:00:00Z